Home
Statistics
Acknowledgment
Enquire
Keyword Search
Complex Search
Segment Search
Peptide Mapping
Browse On
Mode of delivery
Animal model
Origin/Source
Peptide Length
Similarity
BLAST Search
Smith-Waterman
General
Help or Guide
Data Submission
Curators
Developers
Contact Us
Browse result page of B3Pdb
The total number entries retrieved from this search are
9
, scroll left/right for detailed information.
B3pdbID
PEPTIDE NAME
PEPTIDE SEQUENCE (1-letter)
PEPTIDE SEQUENCE (3-letter)
N-TERMINAL MODIFICATION
C-TERMINAL MODIFICATION
CHEMICAL MODIFICATION
PEPTIDE LENGTH
PEPTIDE CONFORMATION
PEPTIDE NATURE
SOURCE/ORIGIN OF PEPTIDE
SMILES
CELL LINE
In vitro
CONCENTRATION
In vitro
METHOD
In vitro
RESULT
ANIMAL MODEL
In vivo
CONCENTRATION
In vivo
MODE OF DELIVERY
In vivo
METHOD
In vivo
RESULT
ACTION
TRANSPORT TYPE
SUBCELLULAR LOCALISATION
COMBINATION
PHYSICAL CONDITION
RESPONSE
RESULT
LABEL
PMID
b3pdb_0006
NR2B9c
KLSSIESDV
LysLeuSerSerIleGluSerAspVal
NA
NA
NA
9
NA
NA
NA
N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(C(C)C)C(=O)O
NA
NA
NA
NA
Rat
NA
Intranasal
HPLC-MS/MS
NR2B9c-WGA-NPs are able to bypass the BBB and effectively transport NR2B9c into the brain and neuron
It can protect neurons against excitotoxicity, reduce ischemic brain injury and ameliorate neurologi
transcytosis
NA
NR2B9c is combined with WGA-modified nanoparticles
ischemic stroke
NA
NA
NA
30428334
b3pdb_0042
MVIIA (ziconotide)
CKGKGAKCSRLMYDCCTGSCRSGKC
CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCys
NA
TAT-transducing domain was fused at C-terminal
NA
25
Linear
Cationic
NA
N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)O
HEK293 cells
NA
Acetic Acid-Induced WRITHING test
Inhibitory activity toward N-type calcium channels.
Kunming mice
NA
Intranasal and Intervenous
Tremor Symptom Test
It induces tremor symptoms
It showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi
Receptor-mediated transcytosis
NA
Comined with TAT-protein
NA
MIC
0.0436 micromolar
NA
31083641
b3pdb_0043
MVIIA-a
CKGKGAKCSRLMYDCCTGSCRSGKCYGRKKRRQRRR
CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCysTyrGlyArgLysLysArgArgGlnArgArgArg
NA
TAT-transducing domain was fused at C-terminal
NA
36
Linear
Cationic
NA
N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O
HEK293 cells
NA
Acetic Acid-Induced WRITHING test
Inhibitory activity toward N-type calcium channels, albeit with a slightly reduced endothelialcacy i
Kunming mice
NA
Intranasal and Intervenous
Tremor Symptom Test
It induces tremor symptoms
It showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi
Receptor-mediated transcytosis
NA
Combined with TAT protein
NA
MIC
0.413 micromolar
NA
31083641
b3pdb_0044
MVIIA-b
CKGKGAKCSRLMYDCCTGSCRSGKCGYGRKKRRQRRR
CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCysGlyTyrGlyArgLysLysArgArgGlnArgArgArg
NA
TAT-transducing domain was fused at C-terminal
NA
37
Linear
Cationic
NA
N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O
HEK293 cells
NA
Acetic Acid-Induced WRITHING test
Inhibitory activity toward N-type calcium channels, albeit with a slightly reduced endothelialcacy i
Kunming mice
NA
Intranasal and Intervenous
Tremor Symptom Test
It induces tremor symptoms
It showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi
Receptor-mediated transcytosis
NA
Combined with TAT protein
NA
MIC
0.379 micromolar
NA
31083641
b3pdb_0045
MVIIA-c
CKGKGAKCSRLMYDCCTGSCRSGKCGGYGRKKRRQRRR
CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCysGlyGlyTyrGlyArgLysLysArgArgGlnArgArgArg
NA
TAT-transducing domain was fused at C-terminal
NA
38
Linear
Cationic
NA
N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)NCC(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O
HEK293 cells
NA
Acetic Acid-Induced WRITHING test
Inhibitory activity toward N-type calcium channels, albeit with a slightly reduced endothelialcacy i
Kunming mice
NA
Intranasal and Intervenous
Tremor Symptom Test
Ii did not induce tremor symptoms.
It showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi
Receptor-mediated transcytosis
NA
Combined with TAT protein
NA
MIC
0.237 micromolar
NA
31083641
b3pdb_0046
MVIIA-d
CKGKGAKCSRLMYDCCTGSCRSGKCGGGYGRKKRRQRRR
CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCysGlyGlyGlyTyrGlyArgLysLysArgArgGlnArgArgArg
NA
TAT-transducing domain was fused at C-terminal
NA
39
Linear
Cationic
NA
N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O
HEK293 cells
NA
Acetic Acid-Induced WRITHING test
Inhibitory activity toward N-type calcium channels, albeit with a slightly reduced endothelialcacy i
Kunming mice
NA
Intranasal and Intervenous
Tremor Symptom Test
It induces tremor symptoms
It showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi
Receptor-mediated transcytosis
NA
Combined with TAT protein
NA
MIC
0.345 micromolar
NA
31083641
b3pdb_0152
MPEG-PCL-Tat
NA
NA
Addition of MPEG and ploygalactolactone
NA
Addition of MPEG and PCL
NA
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
Adult Sprague-Dawley rats
10 microliter
Intranasal
Fluoroscent screening by FITC labbled peptide maass in brain tissue
2.5% fluoroscence observed in brain tissue
NA
NA
NA
NA
NA
NA
NA
NA
23992922
b3pdb_0233
Protamine
VSRRRRRRGGRRRR
ValSerArgArgArgArgArgArgGlyGlyArgArgArgArg
NA
NA
NA
13
Linear
Cationic
Derived from protamine
NA
NA
NA
NA
NA
BALB/c mice
10 microliter per nostril
Intranasal
In vivo imaging
Peptide + BSA combination deleiveerd in brain olfactory bulb and littlebit in cerebral
peptide can deliver drug into brain tissue
NA
NA
Peptide+BSA
NA
NA
NA
NA
27471676
b3pdb_1209
Penetratin
RQIKIWFQNRRMKWKK
NA
NA
NA
NA
16
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
Male Sprague-Dawley rats
2.0 mM
Intranasal
ELISA
L-penetratin increased the systemic absorption of leptin after intranasal administration.
The intranasal coadministration with L-penetratin could deliver leptin to the brain and in particula
Permeability
Hypothalamus
Combined with leptin
Obesity
NA
The intranasal coadministration with L-penetratin has a potential to deliver leptin into the therape
NA
31926192
IIITD/CB
Raghava's Group
IMTECH
CellPPDMOD
